 | • レポートコード：MRC2-11QY04570 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は二次性副甲状腺機能亢進症治療のグローバル市場について調査・分析したレポートです。種類別（手術、医薬品、ビタミンD、カルシウム模倣薬、リン吸着剤）市場規模、用途別（病院薬局、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別二次性副甲状腺機能亢進症治療の競争状況、市場シェア ・世界の二次性副甲状腺機能亢進症治療市場：種類別市場規模 2015年-2020年（手術、医薬品、ビタミンD、カルシウム模倣薬、リン吸着剤） ・世界の二次性副甲状腺機能亢進症治療市場：種類別市場規模予測 2021年-2026年（手術、医薬品、ビタミンD、カルシウム模倣薬、リン吸着剤） ・世界の二次性副甲状腺機能亢進症治療市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局） ・世界の二次性副甲状腺機能亢進症治療市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局） ・北米の二次性副甲状腺機能亢進症治療市場分析：米国、カナダ ・ヨーロッパの二次性副甲状腺機能亢進症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの二次性副甲状腺機能亢進症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の二次性副甲状腺機能亢進症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの二次性副甲状腺機能亢進症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen、OPKO Health、AbbVie、Astellas Pharma、Roche、KAI Pharmaceuticals、Kyowa Hakko Kirin、Leo Pharma、Takeda、Sanofi、Deltanoid Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
Market Analysis and Insights: Global Secondary Hyperparathyroidism Treatment Market
The global Secondary Hyperparathyroidism Treatment market size is projected to reach US$ 3317.1 million by 2026, from US$ 3143.6 million in 2020, at a CAGR of 5.1%% during 2021-2026.
Global Secondary Hyperparathyroidism Treatment Scope and Market Size
Secondary Hyperparathyroidism Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Secondary Hyperparathyroidism Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Market segment by Type, the product can be split into
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
1.4 Market by Type
1.4.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Surgery
1.4.3 Drugs
1.4.4 Vitamin D
1.4.5 Calcimimetics
1.4.6 Phosphate Binders
1.5 Market by Application
1.5.1 Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Secondary Hyperparathyroidism Treatment Market Perspective (2015-2026)
2.2 Global Secondary Hyperparathyroidism Treatment Growth Trends by Regions
2.2.1 Secondary Hyperparathyroidism Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Secondary Hyperparathyroidism Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Secondary Hyperparathyroidism Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Secondary Hyperparathyroidism Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Secondary Hyperparathyroidism Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperparathyroidism Treatment Players by Market Size
3.1.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue (2015-2020)
3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Secondary Hyperparathyroidism Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio
3.2.1 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Secondary Hyperparathyroidism Treatment Revenue in 2019
3.3 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
3.4 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
3.5 Date of Enter into Secondary Hyperparathyroidism Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2015-2020)
4.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
5.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
6.2 Secondary Hyperparathyroidism Treatment Key Players in North America (2019-2020)
6.3 North America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
6.4 North America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
7.2 Secondary Hyperparathyroidism Treatment Key Players in Europe (2019-2020)
7.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
7.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
8 China
8.1 China Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
8.2 Secondary Hyperparathyroidism Treatment Key Players in China (2019-2020)
8.3 China Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
8.4 China Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
9.2 Secondary Hyperparathyroidism Treatment Key Players in Japan (2019-2020)
9.3 Japan Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
9.4 Japan Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
10.2 Secondary Hyperparathyroidism Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
11 India
11.1 India Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
11.2 Secondary Hyperparathyroidism Treatment Key Players in India (2019-2020)
11.3 India Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
11.4 India Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
12.2 Secondary Hyperparathyroidism Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
12.4 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Amgen
13.1.1 Amgen Company Details
13.1.2 Amgen Business Overview
13.1.3 Amgen Secondary Hyperparathyroidism Treatment Introduction
13.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020))
13.1.5 Amgen Recent Development
13.2 OPKO Health
13.2.1 OPKO Health Company Details
13.2.2 OPKO Health Business Overview
13.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Introduction
13.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.2.5 OPKO Health Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Secondary Hyperparathyroidism Treatment Introduction
13.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Astellas Pharma
13.4.1 Astellas Pharma Company Details
13.4.2 Astellas Pharma Business Overview
13.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Introduction
13.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.4.5 Astellas Pharma Recent Development
13.5 Roche
13.5.1 Roche Company Details
13.5.2 Roche Business Overview
13.5.3 Roche Secondary Hyperparathyroidism Treatment Introduction
13.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.5.5 Roche Recent Development
13.6 KAI Pharmaceuticals
13.6.1 KAI Pharmaceuticals Company Details
13.6.2 KAI Pharmaceuticals Business Overview
13.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
13.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.6.5 KAI Pharmaceuticals Recent Development
13.7 Kyowa Hakko Kirin
13.7.1 Kyowa Hakko Kirin Company Details
13.7.2 Kyowa Hakko Kirin Business Overview
13.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Introduction
13.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.7.5 Kyowa Hakko Kirin Recent Development
13.8 Leo Pharma
13.8.1 Leo Pharma Company Details
13.8.2 Leo Pharma Business Overview
13.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Introduction
13.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.8.5 Leo Pharma Recent Development
13.9 Takeda
13.9.1 Takeda Company Details
13.9.2 Takeda Business Overview
13.9.3 Takeda Secondary Hyperparathyroidism Treatment Introduction
13.9.4 Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.9.5 Takeda Recent Development
13.10 Sanofi
13.10.1 Sanofi Company Details
13.10.2 Sanofi Business Overview
13.10.3 Sanofi Secondary Hyperparathyroidism Treatment Introduction
13.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.10.5 Sanofi Recent Development
13.11 Deltanoid Pharmaceuticals
10.11.1 Deltanoid Pharmaceuticals Company Details
10.11.2 Deltanoid Pharmaceuticals Business Overview
10.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
10.11.4 Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
10.11.5 Deltanoid Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Secondary Hyperparathyroidism Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
Table 3. Ranking of Global Top Secondary Hyperparathyroidism Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Surgery
Table 6. Key Players of Drugs
Table 7. Key Players of Vitamin D
Table 8. Key Players of Calcimimetics
Table 9. Key Players of Phosphate Binders
Table 10. Global Secondary Hyperparathyroidism Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Secondary Hyperparathyroidism Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Secondary Hyperparathyroidism Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Secondary Hyperparathyroidism Treatment Market Share by Regions (2015-2020)
Table 14. Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Secondary Hyperparathyroidism Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Secondary Hyperparathyroidism Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Secondary Hyperparathyroidism Treatment Players
Table 21. Global Secondary Hyperparathyroidism Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Secondary Hyperparathyroidism Treatment Market Share by Players (2015-2020)
Table 23. Global Top Secondary Hyperparathyroidism Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2019)
Table 24. Global Secondary Hyperparathyroidism Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
Table 27. Date of Enter into Secondary Hyperparathyroidism Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Secondary Hyperparathyroidism Treatment Market Size Share by Type (2015-2020)
Table 31. Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Secondary Hyperparathyroidism Treatment Market Size Share by Application (2015-2020)
Table 33. Global Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Secondary Hyperparathyroidism Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 37. North America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 39. North America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 43. Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 45. Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 49. China Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 51. China Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 55. Japan Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 57. Japan Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 61. Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 67. India Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 69. India Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Secondary Hyperparathyroidism Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Secondary Hyperparathyroidism Treatment Market Share (2019-2020)
Table 73. Central & South America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Secondary Hyperparathyroidism Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Secondary Hyperparathyroidism Treatment Market Share by Application (2015-2020)
Table 77. Amgen Company Details
Table 78. Amgen Business Overview
Table 79. Amgen Product
Table 80. Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 81. Amgen Recent Development
Table 82. OPKO Health Company Details
Table 83. OPKO Health Business Overview
Table 84. OPKO Health Product
Table 85. OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 86. OPKO Health Recent Development
Table 87. AbbVie Company Details
Table 88. AbbVie Business Overview
Table 89. AbbVie Product
Table 90. AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 91. AbbVie Recent Development
Table 92. Astellas Pharma Company Details
Table 93. Astellas Pharma Business Overview
Table 94. Astellas Pharma Product
Table 95. Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 96. Astellas Pharma Recent Development
Table 97. Roche Company Details
Table 98. Roche Business Overview
Table 99. Roche Product
Table 100. Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 101. Roche Recent Development
Table 102. KAI Pharmaceuticals Company Details
Table 103. KAI Pharmaceuticals Business Overview
Table 104. KAI Pharmaceuticals Product
Table 105. KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 106. KAI Pharmaceuticals Recent Development
Table 107. Kyowa Hakko Kirin Company Details
Table 108. Kyowa Hakko Kirin Business Overview
Table 109. Kyowa Hakko Kirin Product
Table 110. Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 111. Kyowa Hakko Kirin Recent Development
Table 112. Leo Pharma Business Overview
Table 113. Leo Pharma Product
Table 114. Leo Pharma Company Details
Table 115. Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 116. Leo Pharma Recent Development
Table 117. Takeda Company Details
Table 118. Takeda Business Overview
Table 119. Takeda Product
Table 120. Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 121. Takeda Recent Development
Table 122. Sanofi Company Details
Table 123. Sanofi Business Overview
Table 124. Sanofi Product
Table 125. Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 126. Sanofi Recent Development
Table 127. Deltanoid Pharmaceuticals Company Details
Table 128. Deltanoid Pharmaceuticals Business Overview
Table 129. Deltanoid Pharmaceuticals Product
Table 130. Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020) (Million US$)
Table 131. Deltanoid Pharmaceuticals Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Secondary Hyperparathyroidism Treatment Market Share by Type: 2020 VS 2026
Figure 2. Surgery Features
Figure 3. Drugs Features
Figure 4. Vitamin D Features
Figure 5. Calcimimetics Features
Figure 6. Phosphate Binders Features
Figure 7. Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Secondary Hyperparathyroidism Treatment Report Years Considered
Figure 11. Global Secondary Hyperparathyroidism Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Secondary Hyperparathyroidism Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Secondary Hyperparathyroidism Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Secondary Hyperparathyroidism Treatment Market Share by Players in 2019
Figure 16. Global Top Secondary Hyperparathyroidism Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Secondary Hyperparathyroidism Treatment Revenue in 2019
Figure 18. North America Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Secondary Hyperparathyroidism Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
二次電池リサイクルの世界市場（～2026年） Battery recycling is a process that helps reduce the number of batteries being disposed as municipal solid waste. Secondary batteries should be disposed properly, as they comprise several heavy metals and toxic chemicals. A key factor driving the growth of the market is the self-sustainability of ba…- 骨・ミネラル代謝障害治療の世界市場（～2026年） Bone minerals are the inorganic compounds of the bone tissue that helps in strengthening the bones with its plate and globular structures. These minerals are formed from carbonated hydroxyapatite. Bone minerals are dynamic in living beings, it is continuously reabsorbed and build anew in the bone re…
- 二次アルカンスルホン酸塩の世界市場（～2026年） Secondary Alkane Sulfonate (SAS) is an anionic surfactant, also called paraffine sulfonate. It was synthesized for the first time in 1940 and has been used as surfactant since the 1960ies. SAS is one of the major anionic surfactants used in the market of dishwashing, laundry and cleaning products. S…
- 二次アルカンスルホン酸塩（SAS）の世界市場（～2026年） Market Analysis and Insights: Global Secondary Alkane Sulfonate (SAS) Market The global Secondary Alkane Sulfonate (SAS) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Secondary Alkane Sulfonate (SAS) Scope and Market…
- ドライアイ治療薬・装置治療の世界市場（～2026年） Dry eye disease is a condition that affects the tear film and ocular surface. It is medically known as keratoconjunctivitis sicca. It is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. There are primarily two types of dry eye conditions. One is aqueous tear-deficient dry e…